Decreasing Emergency Department Visits in Patients Who Have Received Chemotherapy

As quality measures are set by governing bodies to reflect reimbursement, institutions are becoming not only fiscally responsible but at the same time improving quality of care. Newer and advanced treatments come with increased cost and unique side effects that can be challenging for both patients and providers. Patient education plays a critical part in symptom management and quality of life. Quality initiatives directed at standardized clinical pathways for symptom management and development for urgent cancer care tactics are becoming a standard in cancer care to help reduce ED visits.

Target Audience

This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss CMS measures regarding ED visits in patients who have recently had chemotherapy and the ramifications on quality of care, cost, and patient satisfaction.
  • Describe tools and resources that could be used for standardized educational pathways to help patients with side effect management.
  • Review how data may be collected and shared to help decrease ED visits and demonstrate the impact nursing can have on this important measure.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.

This educational activity is supported by an educational grant from GlaxoSmithKline.

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
11/01/2021
Course expires: 
11/01/2022
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

Penny Moore, DNP, RN, OCN, NEA-BC
The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, 
re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Penny Moore, DNP, RN, OCN, NEA-BC

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Available Credit

  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing